We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+23.96%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$283M
AUM Growth
+$33.2M
Cap. Flow
+$6.04M
Cap. Flow %
2.13%
Top 10 Hldgs %
59.75%
Holding
54
New
16
Increased
6
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
2
BLU
BELLUS Health Inc.
BLU
+$7.61M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.3M
4
GHRS icon
GH Research
GHRS
+$4.95M
5
KRYS icon
Krystal Biotech
KRYS
+$4.29M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$30.5M
2
EPIX
ESSA Pharma
EPIX
+$6.65M
3
FULC icon
Fulcrum Therapeutics
FULC
+$5.34M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.78M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 93.66%
2 Financials 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
51
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-329,134
Closed -$1.89M
EPIX
52
DELISTED
ESSA Pharma
EPIX
– –
-232,896
Closed -$6.65M
SAGE
53
DELISTED
Sage Therapeutics
SAGE
– –
-50,945
Closed -$2.89M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Acuta Capital Partners held 54 positions worth $283M, up 13% from $250M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q3 2021 filing shows 16 new, 6 increased, 10 reduced and 7 closed positions. Its largest new stake was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M. The largest sale was Celldex Therapeutics, an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 87% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q3 2021 buy was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q3 2021, an estimated $5.3M increase.
  • Acuta Capital Partners's biggest Q3 2021 reduction was Celldex Therapeutics, cutting an estimated $30.5M.
  • Acuta Capital Partners fully exited ESSA Pharma in Q3 2021, selling an estimated $6.65M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $283M portfolio in Q3 2021.
  • Acuta Capital Partners opened 16 new positions and closed 7 in Q3 2021.
  • Acuta Capital Partners's portfolio value rose 13% quarter-over-quarter to $283M.

Based on Acuta Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.